Grifols participates at the 3rd International Conference on Research into Alpha-1 Antitrypsin Deficiency, and the 6th International Congress of Alpha-1 Patients
Grifols participates at the 3rd International Conference on Research into Alpha-1 Antitrypsin Deficiency, and the 6th International Congress of Alpha-1 Patients, both taking place in Lisbon (Portugal) during the first week of April.
Patients and researchers from across the world are meeting to discuss the latest scientific advances in alpha-1 antitrypsin deficiency, a rare genetic disease that can cause respiratory illness, particularly emphysema.
From April 5 to 6, leading doctors and researchers analyzed the possibilities offered by new treatments for patients with this condition and other pathologies that have been treated with alpha-1 antitrypsin augmentation therapy, including diabetes, transplant rejection, and auto-immune disorders.
The 6th International Congress of Alpha-1 Antitrypsin Patients is attended by patients and representatives of associations from 34 countries.
Alpha-1 antitrypsin deficiency is a hereditary disease that can cause respiratory illness and liver disease. There are estimated to be around 100,000 people with alpha-1 antitrypsin deficiency in the US, and a similar number in Europe.